ArticleThe journal of headache and pain2026
Selective reduction of thalamic glutathione in migraine in the absence of detectable N-acetylaspartate alterations.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxidative stress has been implicated in migraine pathophysiology, but direct evidence of brain antioxidant alterations and their relationship to neuronal integrity remains limited.
methodsWe conducted a cross-sectional proton magnetic resonance spectroscopy (
resultsGlutathione (GSH) was the only metabolite showing significant group differences (Welch's F = 31.74, p < 0.001, η
conclusionsThese findings indicate selective thalamic GSH reduction in migraine in the absence of detectable NAA alterations. These observations are consistent with reduced thalamic antioxidant capacity that is not accompanied by measurable neuronal loss, although NAA cannot exclude subtle neuronal or synaptic dysfunction. Thalamic GSH may represent a candidate biomarker that requires independent validation, and the potential of antioxidant strategies remains hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.